amlodipine has been researched along with Leukemia, Myeloid, Acute in 13 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
Leukemia, Myeloid, Acute: Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
| Excerpt | Relevance | Reference |
|---|---|---|
| " There was no significant difference in the adverse events rates between RSV 10 mg/AML 5 mg, RSV 20 mg/AML 5 mg, and ATV 20 mg/AML 5 mg." | 7.30 | Randomized, multicenter, parallel, open, phase 4 study to compare the efficacy and safety of rosuvastatin/amlodipine polypill versus atorvastatin/amlodipine polypill in hypertension patient with dyslipidemia. ( Bae, HJ; Cho, EJ; Choi, JY; Han, KR; Hong, BK; Hong, SP; Hyon, MS; Jin, HY; Jung, HW; Kim, CY; Kim, KS; Kim, SY; Kim, U; Lee, JB; Lee, KH; Lee, KJ; Lee, SR; Lee, SY; Nam, CW; Park, CG; Park, SJ; Park, TH; Rhee, MY; Ryu, JK; Seol, SH; Shin, JH; Yang, DH; Yu, GW, 2023) |
| " There are no serious adverse event and no one discontinued medication due to adverse event." | 7.30 | Efficacy and safety of standard dose triple combination of telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg in primary hypertension: A randomized, double-blind, active-controlled, multicenter phase 3 trial. ( Ahn, Y; Cha, KS; Chang, K; Cho, EJ; Choi, DJ; Choi, SY; Doh, JH; Hong, SJ; Hong, SP; Hwang, JY; Hyon, MS; Ihm, SH; Kang, WC; Kim, HS; Kim, MH; Kim, SH; Kim, WS; Kim, YH; Kwon, K; Lee, JH; Lee, N; Lim, SW; Rhee, MY; Shin, J; Son, JW; Yoo, BS, 2023) |
| " The availability of OM combined with HCTZ, AML or both at different dosages makes it a valuable option to customize therapy based on the levels of BP and the clinical characteristics of hypertensive patients." | 7.01 | Single-Pill Combination with Three Antihypertensive Agents to Improve Blood Pressure Control in Hypertension: Focus on Olmesartan-Based Combinations. ( Burnier, M; Redon, J; Volpe, M, 2023) |
| " There was no significant difference in the adverse events rates between RSV 10 mg/AML 5 mg, RSV 20 mg/AML 5 mg, and ATV 20 mg/AML 5 mg." | 3.30 | Randomized, multicenter, parallel, open, phase 4 study to compare the efficacy and safety of rosuvastatin/amlodipine polypill versus atorvastatin/amlodipine polypill in hypertension patient with dyslipidemia. ( Bae, HJ; Cho, EJ; Choi, JY; Han, KR; Hong, BK; Hong, SP; Hyon, MS; Jin, HY; Jung, HW; Kim, CY; Kim, KS; Kim, SY; Kim, U; Lee, JB; Lee, KH; Lee, KJ; Lee, SR; Lee, SY; Nam, CW; Park, CG; Park, SJ; Park, TH; Rhee, MY; Ryu, JK; Seol, SH; Shin, JH; Yang, DH; Yu, GW, 2023) |
| " There are no serious adverse event and no one discontinued medication due to adverse event." | 3.30 | Efficacy and safety of standard dose triple combination of telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg in primary hypertension: A randomized, double-blind, active-controlled, multicenter phase 3 trial. ( Ahn, Y; Cha, KS; Chang, K; Cho, EJ; Choi, DJ; Choi, SY; Doh, JH; Hong, SJ; Hong, SP; Hwang, JY; Hyon, MS; Ihm, SH; Kang, WC; Kim, HS; Kim, MH; Kim, SH; Kim, WS; Kim, YH; Kwon, K; Lee, JH; Lee, N; Lim, SW; Rhee, MY; Shin, J; Son, JW; Yoo, BS, 2023) |
| " The availability of OM combined with HCTZ, AML or both at different dosages makes it a valuable option to customize therapy based on the levels of BP and the clinical characteristics of hypertensive patients." | 3.01 | Single-Pill Combination with Three Antihypertensive Agents to Improve Blood Pressure Control in Hypertension: Focus on Olmesartan-Based Combinations. ( Burnier, M; Redon, J; Volpe, M, 2023) |
| "50%) were the most frequent adverse events." | 1.91 | Efficacy and safety of single pill combination of amlodipine and valsartan in hypertensive Saudi patients. ( Ahmad, A; Alama, MN; Alharthi, TS; Alkreathy, HM; Alluhabi, SI; Alqarni, F; Alrafiah, AR; Damanhouri, ZA, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 13 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ramzy, S | 1 |
| Abdelazim, AH | 1 |
| Shahin, M | 1 |
| Tiris, G | 1 |
| Mehmandoust, M | 1 |
| Lotfy, HM | 2 |
| Erk, N | 1 |
| Joo, SW | 1 |
| Dragoi, EN | 1 |
| Vasseghian, Y | 1 |
| El-Hanboushy, S | 1 |
| Marzouk, HM | 1 |
| Fayez, YM | 1 |
| Abdelkawy, M | 1 |
| Liu, J | 1 |
| Zhang, Y | 1 |
| Li, H | 1 |
| Liu, C | 1 |
| Quan, P | 1 |
| Fang, L | 1 |
| Burnier, M | 1 |
| Redon, J | 1 |
| Volpe, M | 1 |
| Alluhabi, SI | 1 |
| Alkreathy, HM | 1 |
| Alharthi, TS | 1 |
| Alqarni, F | 1 |
| Alama, MN | 1 |
| Ahmad, A | 1 |
| Alrafiah, AR | 1 |
| Damanhouri, ZA | 1 |
| Borghi, C | 2 |
| Jayagopal, PB | 2 |
| Konradi, A | 1 |
| Bortolotto, LA | 2 |
| Degli Esposti, L | 2 |
| Perrone, V | 2 |
| Snyman, JR | 2 |
| Mansour, RSH | 1 |
| Al Khawaja, AY | 1 |
| Hamdan, II | 1 |
| Khalil, EA | 1 |
| Badr El-Din, KM | 1 |
| Salem, H | 1 |
| Derayea, S | 1 |
| Abdelaziz, A | 1 |
| Nagy, DM | 1 |
| Jung, HW | 1 |
| Kim, CY | 1 |
| Hong, SP | 2 |
| Bae, HJ | 1 |
| Choi, JY | 1 |
| Ryu, JK | 1 |
| Lee, JB | 1 |
| Lee, KH | 1 |
| Han, KR | 1 |
| Yang, DH | 1 |
| Park, CG | 1 |
| Yu, GW | 1 |
| Rhee, MY | 2 |
| Park, SJ | 1 |
| Hyon, MS | 2 |
| Shin, JH | 1 |
| Hong, BK | 1 |
| Jin, HY | 1 |
| Lee, SY | 1 |
| Seol, SH | 1 |
| Lee, SR | 1 |
| Kim, SY | 1 |
| Lee, KJ | 1 |
| Cho, EJ | 2 |
| Nam, CW | 1 |
| Park, TH | 1 |
| Kim, U | 1 |
| Kim, KS | 1 |
| Kim, MH | 1 |
| Kim, YH | 1 |
| Chang, K | 1 |
| Choi, DJ | 1 |
| Kang, WC | 1 |
| Shin, J | 1 |
| Kim, SH | 1 |
| Lee, N | 1 |
| Son, JW | 1 |
| Doh, JH | 1 |
| Kim, WS | 1 |
| Hong, SJ | 1 |
| Ahn, Y | 1 |
| Lim, SW | 1 |
| Choi, SY | 1 |
| Hwang, JY | 1 |
| Kwon, K | 1 |
| Cha, KS | 1 |
| Ihm, SH | 1 |
| Lee, JH | 1 |
| Yoo, BS | 1 |
| Kim, HS | 1 |
| Konradi, AO | 1 |
| Poester, VR | 1 |
| Hidalgo, JED | 1 |
| Jardim, LS | 1 |
| Trápaga, MR | 1 |
| Rabello, VBS | 1 |
| Almeida-Paes, R | 1 |
| Zancope-Oliveira, RM | 1 |
| Xavier, MO | 1 |
1 review available for amlodipine and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Single-Pill Combination with Three Antihypertensive Agents to Improve Blood Pressure Control in Hypertension: Focus on Olmesartan-Based Combinations.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Humans; Hydroc | 2023 |
2 trials available for amlodipine and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Randomized, multicenter, parallel, open, phase 4 study to compare the efficacy and safety of rosuvastatin/amlodipine polypill versus atorvastatin/amlodipine polypill in hypertension patient with dyslipidemia.
Topics: Amlodipine; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Humans; Hypertension | 2023 |
Efficacy and safety of standard dose triple combination of telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg in primary hypertension: A randomized, double-blind, active-controlled, multicenter phase 3 trial.
Topics: Aged; Amlodipine; Chlorthalidone; Essential Hypertension; Female; Humans; Hypertension; Leukemia, My | 2023 |
10 other studies available for amlodipine and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Quantitative Analysis of Two Pharmaceutical Combinations Containing Amlodipine with Either Bisoprolol or Candesartan Using Different UV Spectrophotometric Methods.
Topics: Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Bisoprolol; Humans; Leukemi | 2022 |
Simultaneous determination of hydrochlorothiazide, amlodipine, and telmisartan with spectrophotometric and HPLC green chemistry applications.
Topics: Amlodipine; Chromatography, High Pressure Liquid; Humans; Hydrochlorothiazide; Leukemia, Myeloid, Ac | 2022 |
Eco-friendly spectrophotometric evaluation of triple-combination therapies in the treatment strategy of patients suffering from hypertension during coronavirus pandemic - Spectralprint recognition study.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperten | 2022 |
The role of hydrophilic/hydrophobic group ratio of polyvinyl alcohol on the miscibility of amlodipine in orodispersible films: From molecular mechanism study to product attributes.
Topics: Amlodipine; Animals; Drug Compounding; Leukemia, Myeloid, Acute; Polymers; Polyvinyl Alcohol; Rats; | 2023 |
Efficacy and safety of single pill combination of amlodipine and valsartan in hypertensive Saudi patients.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Drug Therapy, Combination; H | 2023 |
Adherence to Triple Single-Pill Combination of Perindopril/Indapamide/Amlodipine: Findings from Real-World Analysis in Italy.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Humans; Hypertension; | 2023 |
IR microspectroscopic investigation of the interaction of some losartan salts with human stratum corneum protein and its effect on losartan transdermal permeation.
Topics: Amlodipine; Humans; Keratins; Leukemia, Myeloid, Acute; Losartan; Pharmaceutical Preparations; Salts | 2023 |
Utilization of erythrosine B in spectrofluorimetric quenching analysis of amlodipine and perindopril in pharmaceutical and biological matrices.
Topics: Amlodipine; Erythrosine; Humans; Leukemia, Myeloid, Acute; Perindopril; Pharmaceutical Preparations; | 2023 |
A real-world analysis of outcomes and healthcare costs of patients on perindopril/indapamide/amlodipine single-pill vs. multiple-pill combination in Italy.
Topics: Adult; Amlodipine; Antihypertensive Agents; Drug Combinations; Health Care Costs; Humans; Hypertensi | 2024 |
Amlodipine and lufenuron as repurposing drugs against
Topics: Amlodipine; Antifungal Agents; Drug Repositioning; Humans; Itraconazole; Leukemia, Myeloid, Acute | 2023 |